Intended for healthcare professionals

News Extra [these Stories Appear Only On The Web]

NICE recommends new treatment for breast and bowel cancer

BMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7400.1166-d (Published 29 May 2003) Cite this as: BMJ 2003;326:1166

Capecitabine-[National Institute for 3-Year Delay?]

Capecitabine [aka Xeloda] has been approved for use
in North America [USA & Canada] in recurrent or metastatic breast cancer since 2000 at the latest.
Adriamycin-based combinations followed by a taxane
are the standard of care; capecitabine should be an obvious
successor.
Another point is that Xeloda is a chemically trivial
modification of 5-fluorouracil, formulated to enhance
tumor targeting and binding.
Is this recommendation really a mark of clinical excellence,
or a long-deferred catch-up in best practice?

Competing interests:  
None declared

Competing interests: No competing interests

30 May 2003
Brian M. Lynch
Senior Research Professor
St. Francis Xavier University, Antigonish B2G 2W5, Nova Scotia, Canada